Dishman Carbogen

Which are the latest news on Dishman Carbogen?

Why is Dishman Carbogen Amcis Ltd falling/rising?

As of 05-Sep, Dishman Carbogen Amcis Ltd's stock price is at 174.40, down 1.52%, and has significantly underperformed with a 29.65% year-to-date decline. The stock shows bearish signals, with decreased investor interest and negative financial results, indicating ongoing financial instability.

As of 05-Sep, Dishman Carbogen Amcis Ltd's stock price is falling, currently at 174.40, which reflects a decrease of 2.7 or 1.52%. The stock has underperformed its sector by 1.47% today and has touched an intraday low of Rs 173.55, indicating a decline of 2%. <BR><BR>The stock's performance over various periods shows significant weakness; it has dropped by 29.65% year-to-date and 33.38% over the past year, while the broader market, represented by the Sensex, has only declined by 10.21% and 5.21% respectively. Additionally, the stock has been trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, which is a bearish signal.<BR><BR>Investor participation has also decreased, with delivery volume falling by 70.16% compared to the 5-day average, indicating a lack of interest from investors. The company has reported negative results for the last three consecutive quarters, with a significant drop in profit after tax (PAT) of 324.6%, and a high debt-to-EBITDA ratio of 5.44 times, suggesting financial instability.<BR><BR>Overall, the combination of poor financial performance, declining investor interest, and underperformance relative to the market contributes to the stock's falling price.

Who are in the management team of Dishman Carbogen?

The management team of Dishman Carbogen includes Chairman Janmejay R Vyas, Whole-time Director Deohooti J Vyas, Managing Director & CFO Arpit J Vyas, and several Independent Directors, along with the Company Secretary Shrima Dave. They are responsible for the company's strategic direction and regulatory compliance.

The management team of Dishman Carbogen includes the following key members:<BR><BR>1. **Janmejay R Vyas** - Chairman (Non-Executive)<BR>2. **Deohooti J Vyas** - Whole-time Director<BR>3. **Arpit J Vyas** - Managing Director & CFO<BR>4. **Sanjay S Majmudar** - Independent Director<BR>5. **Ashok C Gandhi** - Independent Director<BR>6. **Subir Kumar Das** - Independent Director<BR>7. **Rajendra S Shah** - Independent Director<BR>8. **Shrima Dave** - Company Secretary & Compliance Officer<BR>9. **Maitri K Mehta** - Independent Director<BR><BR>This team plays a crucial role in guiding the company's strategic direction and ensuring compliance with regulatory requirements.

What does Dishman Carbogen do?

Dishman Carbogen Amcis Ltd provides Contract Research and Manufacturing Services in the Pharmaceuticals & Biotechnology sector. As of June 2026, it reported net sales of 678 Cr and a net loss of 58 Cr, with a market cap of INR 2,753 Cr.

Overview: <BR>Dishman Carbogen Amcis Ltd is engaged in Contract Research and Manufacturing Services (CRAMS) within the Pharmaceuticals & Biotechnology industry and operates as a small-cap company.<BR><BR>History: <BR>The company was incorporated as Carbogen Amcis (India) Limited in 2007 and changed its name to Dishman Carbogen Amcis Limited on March 27, 2017. The latest quarterly results reported net sales and profit for June 2026.<BR><BR>Financial Snapshot: <BR>Net Sales: 678 Cr (Quarterly Results - Jun 2026) <BR>Net Profit: -58 Cr (Quarterly Results - Jun 2026) <BR>Market Cap: INR 2,753 Cr (Small Cap)<BR><BR>Key Metrics: <BR>P/E: 152.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.31 <BR>Return on Equity: 1.49% <BR>Price to Book: 0.41 <BR><BR>Contact Details: <BR>Address: Dishman Corporate House, Iscon-Bopal Road Ambli Ahmedabad Gujarat : 380058 <BR>Tel: 91-2717-400102/124 <BR>Email: grievance@dishmangroup.com <BR>Website: htts://imdcal.com

Who are the peers of the Dishman Carbogen?

Dishman Carbogen's peers include Kwality Pharma, SMS Pharma, Advanced Enzyme, Ind-Swift Labs, Solara Active, Hikal, Fredun Pharma, Panacea Biotec, and Beta Drugs Ltd. In terms of management risk, Dishman Carbogen is rated Below Average, with a 1-year return of -32.34%, lower than peers like Fredun Pharma, which had the highest return at 279.00%.

Peers: The peers of Dishman Carbogen are Kwality Pharma, SMS Pharma., Advanced Enzyme, Ind-Swift Labs., Solara Active, Hikal, Fredun Pharma, Panacea Biotec, and Beta Drugs Ltd.<BR><BR>Quality Snapshot: Excellent management risk is observed at Kwality Pharma and Advanced Enzyme, while Average management risk is found at SMS Pharma., Hikal, and Beta Drugs Ltd, and the rest. Below Average management risk is noted at Ind-Swift Labs., Solara Active, Dishman Carbogen, Fredun Pharma, and Panacea Biotec. Growth is Excellent at Fredun Pharma, Good at Dishman Carbogen, and Below Average at Kwality Pharma, SMS Pharma., Advanced Enzyme, Ind-Swift Labs., Solara Active, Hikal, Panacea Biotec, and the rest. Capital Structure is Excellent at Kwality Pharma and Advanced Enzyme, Average at SMS Pharma., Ind-Swift Labs., and Hikal, and Below Average at Dishman Carbogen, Solara Active, Fredun Pharma, Panacea Biotec, and Beta Drugs Ltd.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Fredun Pharma at 279.00%, while the peer with the lowest is Advanced Enzyme at -15.05%. Dishman Carbogen's 1-year return is -32.34%, which is lower than both of these peers. Additionally, the peers with a negative six-month return are Advanced Enzyme and Panacea Biotec.

How big is Dishman Carbogen?

As of 31st August, Dishman Carbogen Amcis Ltd has a market capitalization of 2,753.00 Cr, with net sales of 2,901.49 Cr and a net profit of 16.16 Cr reported in the latest four quarters.

As of 31st August, Dishman Carbogen Amcis Ltd has a market capitalization of 2,753.00 Cr, categorizing it as a Small Cap company.<BR><BR>In the latest four quarters, the company reported net sales of 2,901.49 Cr and a net profit of 16.16 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with shareholder's funds amounting to 5,831.52 Cr and total assets of 9,986.34 Cr.

Should I buy, sell or hold Dishman Carbogen Amcis Ltd?

When is the next results date for Dishman Carbogen Amcis Ltd?

The next results date for Dishman Carbogen Amcis Ltd is 14 August 2026.

The next results date for Dishman Carbogen Amcis Ltd is scheduled for 14 August 2026.

Are Dishman Carbogen Amcis Ltd latest results good or bad?

Dishman Carbogen Amcis Ltd's latest Q4 FY26 results show strong revenue growth of 18.85% to ₹851.40 crores, but a concerning 49.55% decline in net profit to ₹21.74 crores, driven by rising costs and a high tax rate. Overall, the results indicate more challenges than positives for the company.

Dishman Carbogen Amcis Ltd's latest results for Q4 FY26 present a mixed picture, with significant concerns overshadowing some positive aspects. On one hand, the company achieved record-high quarterly revenue of ₹851.40 crores, reflecting an impressive year-on-year growth of 18.85%. This indicates strong demand for its services and successful client acquisition.<BR><BR>However, the net profit for the same quarter was ₹21.74 crores, which represents a drastic decline of 49.55% compared to the previous year. This sharp drop in profitability is alarming, particularly as it coincides with a significant increase in employee costs, which rose by over 25% year-on-year. The operating margin also contracted to 19.14%, down from 21.32% a year ago, indicating that while revenues are growing, the company's ability to convert those revenues into profit is deteriorating.<BR><BR>Additionally, the profit after tax margin fell to just 2.55%, down from 6.02% in the same quarter last year, highlighting serious operational challenges. The extraordinarily high tax rate of 52.87% further exacerbated the decline in net profit, raising concerns about the sustainability of the company's business model.<BR><BR>In summary, while Dishman Carbogen's revenue growth is commendable, the significant drop in net profit and ongoing cost pressures suggest that the latest results are more concerning than positive. Investors may need to closely monitor the company's ability to address these challenges moving forward.

Is Dishman Carbogen technically bullish or bearish?

As of December 2, 2025, the market trend for Dishman Carbogen has shifted to mildly bearish, indicated by bearish MACD readings and Bollinger Bands on the weekly chart, despite some short-term support from daily moving averages.

As of 2 December 2025, the technical trend has changed from sideways to mildly bearish. The current stance is mildly bearish, supported by the weekly and monthly MACD readings, both indicating a bearish momentum. The Bollinger Bands show a bearish signal on the weekly chart, while the daily moving averages are mildly bullish, suggesting some short-term support. The KST and OBV are also mildly bearish on the weekly timeframe. Overall, the combination of these indicators points to a bearish sentiment in the current market environment for Dishman Carbogen.

How has been the historical performance of Dishman Carbogen?

Dishman Carbogen's historical performance shows steady growth in net sales from INR 2,140.69 crore in March 2022 to INR 2,711.50 crore in March 2025, with improved profitability indicators, including a profit after tax of INR 3.24 crore in March 2025. Total liabilities and assets increased, reflecting a stronger financial position, while cash flow from operations remained stable.

Answer:<BR>The historical performance of Dishman Carbogen shows a fluctuating trend in key financial metrics over the years leading up to March 2025.<BR><BR>Breakdown:<BR>Dishman Carbogen's net sales have shown a steady increase from INR 2,140.69 crore in March 2022 to INR 2,711.50 crore in March 2025. The total operating income followed a similar trend, rising from INR 2,140.69 crore in March 2022 to INR 2,711.50 crore in March 2025. However, the total expenditure, excluding depreciation, increased from INR 1,809.32 crore in March 2022 to INR 2,242.56 crore in March 2025, impacting the operating profit, which saw a rise to INR 468.94 crore in March 2025 from INR 331.37 crore in March 2022. Despite this, the profit before tax turned positive at INR 19.31 crore in March 2025 after being negative in the previous years. The profit after tax also improved to INR 3.24 crore in March 2025 from a loss of INR 153.45 crore in March 2024. On the balance sheet, total liabilities increased to INR 9,986.34 crore in March 2025 from INR 8,634.20 crore in March 2022, while total assets rose to INR 9,986.34 crore in March 2025, indicating a growth in the company's financial position. Cash flow from operating activities remained relatively stable, with INR 375 crore in March 2025, while net cash inflow was recorded at INR 76 crore for the same period. Overall, Dishman Carbogen has shown signs of recovery and growth in its financial performance over the past few years.

Is Dishman Carbogen overvalued or undervalued?

As of November 6, 2025, Dishman Carbogen is considered fairly valued with a PE ratio of 28.07, an EV to EBITDA of 10.39, and a Price to Book Value of 0.72, outperforming the Sensex with a 37.05% return over the past year.

As of 6 November 2025, Dishman Carbogen's valuation grade has moved from very attractive to attractive, indicating a shift in market perception. The company is currently considered fairly valued. Key ratios include a PE ratio of 28.07, an EV to EBITDA of 10.39, and a Price to Book Value of 0.72. <BR><BR>In comparison to its peers, Dishman Carbogen's PE ratio is lower than that of Sun Pharma, which stands at 35.02, and significantly lower than Divi's Lab at 79.09. However, it is on par with Cipla, which has a PE of 22.27, and Dr. Reddy's Labs at 17.42. Notably, Dishman Carbogen has outperformed the Sensex over the past year with a return of 37.05% compared to the Sensex's 3.65%, reinforcing its current valuation status.

Who are the top shareholders of the Dishman Carbogen?

The top shareholders of Dishman Carbogen include Adimans Technologies LLP with 59.32%, individual investors with 25.31%, and Mukul Mahavir Agrawal holding 5.5%. Additionally, foreign institutional investors hold 9.49%, and mutual funds have a combined stake of 1.06%, with no pledged promoter holdings reported.

The top shareholders of Dishman Carbogen include the promoters, with Adimans Technologies LLP holding the highest stake at 59.32%. Additionally, individual investors collectively own 25.31% of the company. Among public shareholders, Mukul Mahavir Agrawal is notable with a holding of 5.5%. The company also has 61 foreign institutional investors (FIIs) holding 9.49% and 6 mutual fund schemes with a combined holding of 1.06%. There are no pledged promoter holdings reported.

Has Dishman Carbogen declared dividend?

Dishman Carbogen Amcis Ltd has declared a 10% dividend, amounting to ₹0.2 per share, with an ex-date of September 12, 2019. However, there have been no dividends declared since then, resulting in a 0% dividend return across multiple periods despite significant price returns.

Dishman Carbogen Amcis Ltd has declared a 10% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 10%<BR>- Amount per share: 0.2<BR>- Ex-date: 12 Sep 19<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -0.48%, the dividend return was 0%, resulting in a total return of -0.48%.<BR><BR>Over the past year, the price return was 85.25%, with a dividend return of 0%, leading to a total return of 85.25%.<BR><BR>In the last 2 years, the price return was 116.96%, while the dividend return remained at 0%, culminating in a total return of 116.96%.<BR><BR>For the 3-year period, the price return was 124.29%, with a dividend return of 0%, resulting in a total return of 124.29%.<BR><BR>In the 4-year period, the price return was 27.47%, and the dividend return was 0%, leading to a total return of 27.47%.<BR><BR>Over the last 5 years, the price return was 273.97%, with a dividend return of 0%, resulting in a total return of 273.97%.<BR><BR>Overall, Dishman Carbogen has declared a dividend in the past, but there have been no dividends declared since then, as indicated by the 0% dividend return across multiple periods. The company has shown significant price returns over the years, particularly in the 5-year period, despite the absence of recent dividends.